Side-by-side · Research reference
IGF-DESvsN-Acetyl Epitalon Amidate
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED8/60 cited
BAnimal-StrongHUMAN-REVIEWED12/45 cited
IGF-DES
IGF-1 Analogue · Truncated N-Terminal
~10×Potency vs IGF-1
ReducedIGFBP binding
ResearchStatus
Injection (local or systemic) · Research protocols onlyBredehöft 2008
N-Acetyl Epitalon Amidate
Bioregulator Tetrapeptide · Khavinson School
SQ · Variable protocols
01Mechanism of Action
Parameter
IGF-DES
N-Acetyl Epitalon Amidate
Primary target
IGF-1 receptor (IGF1R)Shields 2007
DNA promoter regions (telomerase, RNA polymerase II, retinal genes)
Pathway
IGF1R activation → PI3K/Akt & MAPK signaling → protein synthesis, proliferation
Peptide → DNA complementary binding → Gene transcription initiation → Telomerase catalytic subunit expression
Downstream effect
Enhanced muscle protein synthesis, myoblast differentiation, reduced apoptosis, cell proliferation
Telomerase enzymatic activity induction, telomere elongation to early-passage length, extension of replicative lifespan in human somatic cellsKhavinson 2003Khavinson 2004
Feedback intact?
Unknown — no human endocrine feedback data
—
Origin
Synthetic truncation of native IGF-1 — removal of N-terminal Gly-Pro-Glu tripeptideBredehöft 2008
Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal extract bioregulator research; N-acetyl and C-amide modifications enhance plasma stability
Antibody development
—
—
02Dosage Protocols
Parameter
IGF-DES
N-Acetyl Epitalon Amidate
Research dose range
10–100 ng/mL (in vitro); μg doses (animal models)
Highly context-dependent; no standardized human protocol.
—
Route
Subcutaneous or intramuscular (local injection favored)
Local delivery maximizes tissue-specific uptake.
—
Frequency
Variable — daily to multiple times daily in research
Not specified in candidate papers
Human data
None — no clinical trials
—
Half-life
Shorter than IGF-1 due to reduced IGFBP binding
Rapid tissue uptake, limited systemic circulation.
—
Standard dose
—
No standardized human dosing in indexed literature
In vitro protocols use direct culture addition; human clinical dosing protocols are in Russian-language literature outside PubMed scope.
Cell culture protocol
—
Addition to human fetal fibroblast culture induced telomerase activity and telomere elongation to early-passage lengthKhavinson 2004
Cells made 10 extra divisions (44 passages total vs 34 in control).
Duration
—
Chronic treatment in aging culture
Sustained effect through late passages.
Modification stability
—
N-acetyl + C-amide caps enhance peptidase resistance
Standard strategy for tetrapeptide stabilization; specifics not quantified in candidates.
03Metabolic / Fat Loss Evidence
Parameter
IGF-DES
N-Acetyl Epitalon Amidate
Primary mechanism
Indirect via muscle hypertrophy → metabolic rate elevation
—
Direct lipolysis
Minimal evidence — IGF-1 axis primarily anabolic, not lipolytic
—
Prostate model
Inhibited BPH cell proliferation when combined with vitamin D3 analogueCrescioli 2002
Context-specific anti-proliferative effect, not fat loss.
—
04Side Effects & Safety
Parameter
IGF-DES
N-Acetyl Epitalon Amidate
Hypoglycemia risk
Theoretical — IGF-1 axis enhances glucose uptake
—
Mitogenic risk
Chronic IGF-1 receptor activation may promote cell proliferation, potential tumor growthCrescioli 2002
—
Injection site reaction
Expected — erythema, irritation, local swelling
—
Edema / Fluid retention
Possible via sodium retention (IGF-1 axis effect)
—
Human safety data
Absent — no human trials, all effects theoretical or extrapolated
Not available in indexed literature
Candidate papers describe in vitro and animal models only.
Unknown long-term effects
No chronic dosing studies in humans; endocrine, metabolic consequences unknown
—
Theoretical telomerase risk
—
Telomerase activation in somatic cells raises theoretical oncogenic transformation concern
Absolute Contraindications
IGF-DES
- ·Active malignancy or history of cancer (mitogenic risk)
- ·Pregnancy / lactation (no safety data)
- ·Hypoglycemia disorders
N-Acetyl Epitalon Amidate
- ·Active malignancy or history of cancer — telomerase reactivation may promote tumor cell immortalization
Relative Contraindications
IGF-DES
- ·Diabetes mellitus (unpredictable glucose effects)
- ·Renal or hepatic impairment (clearance unknown)
- ·Edema-prone conditions (heart failure, nephrotic syndrome)
N-Acetyl Epitalon Amidate
- ·Individuals with hereditary cancer syndromes or high genetic cancer risk
05Administration Protocol
Parameter
IGF-DES
N-Acetyl Epitalon Amidate
1. Research context only
Des(1-3)IGF-1 has no approved human protocol. All administration details are derived from animal or in vitro research and should not be construed as medical guidance.
Subcutaneous injection assumed based on peptide class; no specific protocol in candidate papers.
2. Reconstitution (if lyophilized)
Sterile water or bacteriostatic water per research protocol. Gently swirl; do not shake. Store reconstituted peptide at 2–8 °C.
Standard bacteriostatic water for lyophilized peptides. Exact volume not specified in indexed literature.
3. Injection site
Subcutaneous (abdomen, thigh) or intramuscular (deltoid, vastus lateralis). Local injection to target tissue (e.g., muscle group) may enhance regional uptake.
Lyophilized: -20 °C, desiccated. Reconstituted: refrigerate 2–8 °C. N-acetyl and C-amide modifications improve stability vs unprotected tetrapeptide.
4. Timing
Frequency and timing vary by research design. Post-exercise or fasted state may theoretically enhance muscle uptake.
Human dosing schedules published in Russian-language clinical literature; not indexed in PubMed candidate set.
5. Needle gauge
27–31G insulin syringe for subcutaneous; 25–27G for intramuscular.
—
6. Monitoring
Glucose monitoring essential (hypoglycemia risk). No established IGF-1 or safety labs for human use.
—
06Stack Synergy
IGF-DES
+ BPC-157
ModerateDes(1-3)IGF-1 promotes myoblast differentiation and protein synthesis, while BPC-157 enhances tissue repair, angiogenesis, and collagen synthesis. Both act on distinct pathways (IGF1R vs gastric pentadecapeptide mechanisms) to support muscle recovery and connective tissue integrity. Synergy is mechanistic but lacks direct co-administration studies.
- Des(1-3)IGF-1
- Research dose post-workout (local IM)
- BPC-157
- 250–500 mcg SQ, daily or twice daily
- Frequency
- Daily or per research protocol
- Primary benefit
- Accelerated muscle repair, enhanced hypertrophy, connective tissue support
+ TB-500
ModerateTB-500 (Thymosin Beta-4 fragment) promotes cell migration, angiogenesis, and wound healing via actin regulation. Des(1-3)IGF-1 drives protein synthesis and myoblast proliferation. Combined, these peptides may synergistically enhance muscle recovery, repair, and hypertrophy through complementary anabolic and regenerative pathways. No direct human co-administration data.
- Des(1-3)IGF-1
- Research dose post-workout (local IM)
- TB-500
- 2–5 mg SQ, 2× weekly
- Frequency
- Per research cycle
- Primary benefit
- Muscle hypertrophy, injury recovery, vascular support
N-Acetyl Epitalon Amidate
+ Thymalin
ModerateBoth are Khavinson-school bioregulators with epigenetic mechanisms. Thymalin targets thymic transcription factors for immune function, while Epitalon targets telomerase and pineal-axis genes. Combined use theoretically addresses dual axes of aging: replicative senescence and immune decline. Multi-target bioregulator strategy per Khavinson gerontology framework.
- Epitalon
- Protocol not defined in indexed literature
- Thymalin
- Tissue-specific bioregulator · separate dosing
- Rationale
- Complementary transcriptional targets
- Primary benefit
- Dual-axis aging intervention: cellular senescence + immune restoration